Previous close | 7.20 |
Open | 5.90 |
Bid | 3.80 |
Ask | 7.50 |
Strike | 105.00 |
Expiry date | 2024-05-17 |
Day's range | 5.90 - 5.90 |
Contract range | N/A |
Volume | |
Open interest | 26 |
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript May 2, 2024 Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64. Blueprint Medicines Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. […]
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
Blueprint Medicines reports robust Q1 earnings, raises EBITDA outlook, and progresses in key pipeline developments.